ARGUN AKCAKANAT to Proto-Oncogene Proteins c-akt
This is a "connection" page, showing publications ARGUN AKCAKANAT has written about Proto-Oncogene Proteins c-akt.
Connection Strength
0.634
-
Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer. 2008 Jun; 112(11):2352-8.
Score: 0.183
-
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
Score: 0.098
-
Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway. Mol Ther. 2014 Jul; 22(7):1310-1319.
Score: 0.068
-
Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am. 2013 Oct; 22(4):641-64.
Score: 0.065
-
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012 Mar 15; 18(6):1777-89.
Score: 0.059
-
The effect of leucine restriction on Akt/mTOR signaling in breast cancer cell lines in vitro and in vivo. Nutr Cancer. 2011; 63(2):264-71.
Score: 0.055
-
eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther. 2008 Jul; 7(7):1782-8.
Score: 0.046
-
Rapamycin regulates the phosphorylation of rictor. Biochem Biophys Res Commun. 2007 Oct 19; 362(2):330-3.
Score: 0.043
-
PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014 Apr; 2(4):361-70.
Score: 0.017